Bill Summary for S 156 (2019-2020)

Printer-friendly: Click to view

Summary date: 

Jun 25 2020

Bill Information:

View NCGA Bill Details2019-2020 Session
Senate Bill 156 (Public) Filed Wednesday, February 27, 2019
AN ACT TO CLARIFY WHEN SUBSEQUENT COURT ORDERS WILL SUPERSEDE SIMILAR PROVISIONS IN DOMESTIC VIOLENCE PROTECTIVE ORDERS; TO ALLOW THE DEPARTMENT OF PUBLIC SAFETY TO RELOCATE ALCOHOL LAW ENFORCEMENT AS SUITABLE STATE-OWNED PROPERTY IS IDENTIFIED; AND TO DIRECT THE COMMISSION FOR MENTAL HEALTH, DEVELOPMENTAL DISABILITIES, AND SUBSTANCE ABUSE SERVICES TO EXCLUDE CERTAIN DRUG PRODUCTS FROM SCHEDULING IN THE CONTROLLED SUBSTANCES ACT.
Intro. by J. Jackson, Bishop, Daniel.

View: All Summaries for BillTracking:

Bill summary

House committee substitute makes the following changes to the 3rd edition. Deletes the content of the 3rd edition and instead provides the following.

Section 1

Amends GS 50B-7 to provide that any subsequent order under GS Chapters 50 (Divorce and Alimony) or 110 (Child Welfare) supersedes similar provisions in prior protective orders issued pursuant to GS Chapter 50B (Domestic Violence). 

Amends GS 50B-2 to require a party seeking relief under the Chapter to disclose in its pleadings or attached affidavit any existing GS Chapter 50, 50B, or 110 orders between the parties. Bars any relief granted under the Chapter in reliance upon that party's pleading or attached affidavit lacking the required disclosures from superseding any similar provision in the prior order(s).

Applies to orders in effect on or after the date the act becomes law.

Section 2

Allows the Department of Public Safety (DPS) to begin to relocate the ALE headquarters and regional office as State-owned space if identified or recurring funds is secured. Until then, requires DPS to continue with the consolidation of ALE and SBE regions and regional offices so that district offices are co-located. Effective when the act becomes law.

Section 3

Enacts GS 90-88(j) to require exclusion from any controlled substance schedule a US FDA-approved drug product in finished dosage formulation that contains cannabidiol derived from cannabis with no more than 1/10th of 1% residual tetrahydrocannabinols by weight. Effective August 1, 2020, and applies to offenses committed on or after that date.

Makes conforming changes to the act's titles.